Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Front-line blinatumomab plus chemotherapy and tyrosine kinase inhibitor for pediatric Philadelphia chromosome-positive or Ph-like acute lymphoblastic leukemia
MOH_2025-12-30_015573Phase 3Not yet recruiting
- Sponsor
- University of Milano-Bicocca
- Start
- Sep 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label trial of blinatumomab in acute lymphoblastic leukemia (ALL) and Philadelphia-chromosome positive acute lymphoblastic leukemia (2 arms), sponsored by University of Milano-Bicocca. Planned start Sep 2025; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)Philadelphia-chromosome positive acute lymphoblastic leukemia
Beyond the preview
Go deeper on MOH_2025-12-30_015573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2025-12-30_015573.